Vasculitis in the Geriatric Population

Rheumatic Disease Clinics of North America

Volumn 33, Issue 1, 2007, Pages 177-195

  Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISONE;

ANAPHYLACTOID PURPURA; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COMORBIDITY; CYTOPENIA; DIABETES MELLITUS; GERIATRICS; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; MICROSCOPIC POLYANGIITIS; MYOPATHY; OSTEOPOROSIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; VASCULITIS; WEGENER GRANULOMATOSIS;

AGED; BLOOD SEDIMENTATION; CHURG-STRAUSS SYNDROME; COMORBIDITY; HUMANS; PNEUMONIA, PNEUMOCYSTIS; POLYMYALGIA RHEUMATICA; PURPURA, SCHOENLEIN-HENOCH; RECURRENCE; TEMPORAL ARTERITIS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 33947118313     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.12.002     Document Type: Review

References (110)

1. Kussmaul A, Maier R. Über eine bischer nicht beschriebene, eigentümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellåhmung einhergeht. Deutsches Arch klin Med 1866;1:484-518.
2. Zeek P.M. Periarteritis nodosa: critical review. Am J Pathol 22 (1952) 777-790
3. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
4. Watts R.A., and Scott D.G. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 11 (1997) 191-217
5. Weyand C.M., and Goronzy J.J. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139 (2003) 505-515
6. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
7. Salvarani C., Crowson C.S., O'Fallon W.M., et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 51 (2004) 264-268
8. Calamia K.T., and Hunder G.G. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 6 (1980) 389-403
9. Aiello P.D., Trautmann J.C., McPhee T.J., et al. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
10. Hayreh S.S., Podhajsky P.A., and Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125 (1998) 509-520
11. Brack A., Martinez-Taboada V., Stanson A., et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 42 (1999) 311-317
12. Achkar A.A., Lie J.T., Hunder G.G., et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med 120 (1994) 987-992
13. Birkhead N.C., Wagener H.P., and Shick R.M. Treatment of temporal arteritis with adrenal corticosteroids. JAMA 163 (1957) 821-827
14. Myles A.B., Perera T., and Ridley M.G. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 31 (1992) 103-105
15. Ross Russell R.W. Giant cell arteritis. QJM 112 (1959) 471-489
16. Liu G.T., Glaser J.S., Schatz N.J., et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 101 (1994) 1779-1785
17. Fauchald P., Rygvold O., and Oystase B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med 77 (1972) 845-852
18. Huston K.A., Hunder G.G., Lie J.T., et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 88 (1978) 162-167
19. Sorensen S., and Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand 201 (1977) 207-213
20. Bengtsson B.A., and Malmvall B.E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 209 (1981) 337-345
21. Lundberg I., and Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 17 (1990) 1340-1345
22. Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. J Rheumatol 7 (1980) 361-364
23. Jover J.A., Hernandez-Garcia C., Morado I.C., et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
24. Hoffman G.S., Cid M.C., Hellmann D.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
25. Nesher G., Berkun Y., Mates M., et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
26. Evans J.M., Bowles C.A., Bjornsson J., et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 37 (1994) 1539-1547
27. Evans J.M., O'Fallon W.M., and Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122 (1995) 502-507
28. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 18 (2004) 705-722
29. Chuang T.Y., Hunder G.G., Ilstrup D.M., et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 97 (1982) 672-680
30. Weyand C.M., Tetzlaff N., Bjornsson J., et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40 (1997) 19-26
31. Weyand C.M., Hicok K.C., Hunder G.G., et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121 (1994) 484-491
32. Weyand C.M., Fulbright J.W., Evans J.M., et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159 (1999) 577-584
33. Caporali R., Cimmino M.A., Ferraccioli G., et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141 (2004) 493-500
34. Stone J.H. Methotrexate in polymyalgia rheumatica: kernel of truth or curse of Tantalus?. Ann Intern Med 141 (2004) 568-569
35. Guillevin L., Lhote F., Guillevin L., et al. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 7 (1995) 20-24
36. Watts R.A., Jolliffe V.A., Carruthers D.M., et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 39 (1996) 1208-1212
37. Guillevin L., Visser H., Noel L.H., et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome-62 patients. J Rheumatol 20 (1993) 1345-1349
38. Fauci A.S., Doppman J.L., and Wolff S.M. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 64 (1978) 890-894
39. Gayraud M., Guillevin L., le Toumelin P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44 (2001) 666-675
40. Guillevin L., and Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 41 (1998) 2100-2105
41. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 (1996) 17-28
42. Guillevin L., Lhote F., and Gherardi R. The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumatol 9 (1997) 31-36
43. Guillevin L., Lhote F., Cohen P., et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74 (1995) 238-253
44. Guillevin L., Lhote F., Sauvaget F., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 53 (1994) 334-337
45. Guillevin L., Lhote F., Leon A., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 20 (1993) 289-298
46. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
47. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43 (2000) 1021-1032
48. Tidman M., Olander R., Svalander C., et al. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 244 (1998) 133-141
49. Watts R.A., Lane S.E., Bentham G., et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43 (2000) 414-419
50. van der Woude F.J., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1 (1985) 425-429
51. Hoffman G.S., and Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41 (1998) 1521-1537
52. Niles J.L., McCluskey R.T., Ahmad M.F., et al. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 74 (1989) 1888-1893
53. Falk R.J., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318 (1988) 1651-1657
54. Nölle B., Specks U., Lüdemann J., et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 111 (1989) 28-40
55. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43 (2000) 2025-2033
56. Kerr G.S., Fleisher T.A., Hallahan C.W., et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 36 (1993) 365-371
57. Falk R.J., and Jennette J.C. ANCA are pathogenic-oh yes they are!. J Am Soc Nephrol 13 (2002) 1977-1979
58. Russell K.A., and Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am 27 (2001) 815-832
59. Travis W.D., Hoffman G.S., Leavitt R.Y., et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15 (1991) 315-333
60. Devaney K.O., Travis W.D., Hoffman G.S., et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14 (1990) 555-564
61. Jennette J.C., and Falk R.J. The pathology of vasculitis involving the kidney. Am J Kidney Dis 24 (1994) 130-141
62. Fauci A., and Wolff S. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine 52 (1973) 535-561
63. Fauci A., Haynes B., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98 (1983) 76-85
64. Langford C.A., Talar-Williams C., Barron K.S., et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
65. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
66. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 (1996) 477-484
67. Reinhold-Keller E., Fink C.O., Herlyn K., et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47 (2002) 326-332
68. Nowack R., Göbel U., Klooker P., et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 (1999) 1965-1971
69. Langford C.A., Talar-Williams C., and Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51 (2004) 278-283
70. De Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
71. Sneller M.C., Hoffman G.S., Talar-Williams C., et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38 (1995) 608-613
72. Hoffman G.S., and Langford C.A. Are there different forms of life in the antineutrophil cytoplasmic antibody universe?. Ann Intern Med 143 (2005) 683-685
73. WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
74. Stone J.H., Holbrook J.T., Marriott M.A., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54 (2006) 1608-1618
75. Booth A., Harper L., Hammad T., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
76. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
77. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
78. Stegeman C.A., Cohen Tervaert J.W., de Jong P.E., et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 335 (1996) 16-20
79. Govert J.A., Patton S., and Fine R.L. Pancytopenia from using trimethoprim and methotrexate. [letter]. Ann Intern Med 117 (1992) 877-878
80. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 (1999) 421-430
81. Savage C.O., Winearls C.G., Evans D.J., et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56 (1985) 467-483
82. Nachman P.H., Hogan S.L., Jennette J.C., et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7 (1996) 33-39
83. Churg J., and Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 27 (1951) 277-301
84. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 (1999) 26-37
85. Lanham J.G., Elkon K.B., Pusey C.D., et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63 (1984) 65-81
86. Chumbley L.C., Harrison Jr. E.G., and DeRemee R.A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 52 (1977) 477-484
87. Weller P.F., Plaut M., Taggart V., et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 108 (2001) 175-183
88. Stone J.H., and Nousari H.C. "Essential" cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin. Curr Opin Rheumatol 13 (2001) 23-34
89. Lotti T., Ghersetich I., Comacchi C., et al. Cutaneous small-vessel vasculitis. J Am Acad Dermatol 39 (1998) 667-687 [quiz: 88-90]
90. Gibson L.E. Cutaneous vasculitis: approach to diagnosis and systemic associations. Mayo Clin Proc 65 (1990) 221-229
91. Saulsbury F.T. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 78 (1999) 395-409
92. Fogazzi G.B., Pasquali S., Moriggi M., et al. Long-term outcome of Schonlein-Henoch nephritis in the adult. Clin Nephrol 31 (1989) 60-66
93. Ballard H.S., Eisenger R.P., and Gallo G. Renal manifestations of Henoch-Schonlein syndrome in adults. Am J Med 49 (1970) 328-335
94. Blanco R., Martinez-Taboada V.M., Rodriguez-Valverde V., et al. Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 40 (1997) 859-864
95. Choi H.K., Merkel P.A., Walker A.M., et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43 (2000) 405-413
96. Lamprecht P., Gause A., and Gross W.L. Cryoglobulinemic vasculitis. Arthritis Rheum 42 (1999) 2507-2516
97. Agnello V., and Romain P.L. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 22 (1996) 1-21
98. Vassilopoulos D., and Calabrese L.H. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 46 (2002) 585-597
99. Dammacco F., Sansonno D., Han J.H., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84 (1994) 3336-3343
100. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
101. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
102. Nesher G., Sonnenblick M., and Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21 (1994) 1283-1286
103. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 (1997) 2187-2198
104. Matteson E.L., Gold K.N., Bloch D.A., et al. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 101 (1996) 129-134
105. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 151 (1995) 795-799
106. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 327 (1992) 1853-1860
107. Gabriel S.E., Sunku J., Salvarani C., et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40 (1997) 1873-1878
108. Pearce G., Ryan P.F., Delmas P.D., et al. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 37 (1998) 292-299
109. el-Gamel A., Evans C., Keevil B., et al. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients. Transplant Proc 30 (1998) 1127-1129
110. Prager D., Rosman M., and Bertino J.R. Letter: azathioprine and allopurinol. Ann Intern Med 80 (1974) 427